# Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

> **NCT00411333** · EARLY_PHASE1 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 100 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** triamcinolone acetonide (Kenalog)

## Key facts

- **NCT ID:** NCT00411333
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2010-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411333, "Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00411333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*